US NHGRI Launches Major Effort to Identify Race-Specific Drug Targets for Type 2 Diabetes in Yoruba Population Through GWAS Study
Addressing the Scarcity of African Genetic Data
Currently, over 80% of global genome-wide association study (GWAS) data is skewed towards individuals of European ancestry, limiting the development of new drugs for diverse populations. This West African Yoruba population-based Type 2 Diabetes genetics study, led by the US National Human Genome Research Institute (NHGRI), aims to overcome this data bias. By comparing 300 patients and 300 controls, the study aims to identify genetic variants unique to African populations that contribute to disease susceptibility. This will undoubtedly become a valuable genetic asset for global pharmaceutical companies seeking to target underserved emerging markets.
Building a Precision Medicine Framework for Diagnosis and Prevention
This research goes beyond simply identifying the presence or absence of diabetes by collecting comprehensive phenotypic data, including blood pressure, body composition, and eye exams. This will allow researchers to functionally validate whether variants identified in previous studies of European populations function similarly in West African populations. In particular, replication studies of the top 100 variants and whole-genome resequencing will enable the refinement of genetic risk scores for the disease. This is expected to form the basis of precision medicine, providing personalized prevention and treatment solutions for African patients.
Expanding the Potential of the Underserved Diabetes Market
The global Type 2 diabetes market is estimated at approximately $43.3 billion to $45 billion by 2026, and prevalence is rapidly increasing in developing countries, including Africa. While GLP-1 (Glucagon-like peptide-1) agonists such as Ozempic (Semaglutide) from Novo Nordisk (NVO) and Mounjaro (Tirzepatide) from Eli Lilly (LLY) currently dominate the market, there is still a lack of genetically optimized data for African populations. The discovery of Africa-specific targets could lead to the development of new targeted therapies for patients who do not respond to existing standard treatments.
Long-Term Investment Value from a Venture Capital Perspective
The genetics research (GWAS) stage is at an early, foundational level, making it difficult to realize immediate commercial benefits. However, it is a valuable long-term investment because it allows for the acquisition of exclusive genetic information. In the future, there is likely to be increased activity in co-development or licensing agreements with biotech companies that have target discovery platforms based on the identified gene variants. Therefore, investors should view this research as a signal to gain a foothold in the African precision medicine market and incorporate it into their early-stage new drug development venture investment portfolios.
This research secures African genetic data in the global Type 2 diabetes treatment market, estimated at approximately $43.3 billion by 2026, addressing the disparity in treatment between races and paving the way for long-term breakthroughs in identifying new targets. Researchers will analyze 300 patients and 300 controls from the Yoruba population to identify Africa-specific susceptibility variants that can overcome the limitations of the current diabetes treatment market, led by Novo Nordisk (Novo Nordisk) and Eli Lilly (Eli Lilly). Although it is in the observational and genomic analysis (GWAS) stage before clinical trials, it does not generate short-term revenue, but the acquisition of exclusive variants as biomarkers is a strategic asset that increases the probability of success in late-stage clinical trial design. For researchers and industry professionals, it provides an opportunity to secure the diversity of research through the construction of a multi-racial genome database, and in the medium to long term, it is expected to play a key intellectual property (IP) role in establishing partnerships with global pharmaceutical companies. As a result, this genetic information database will function as an essential foundational asset for the development of precision medicine new drugs targeting the African population, enhancing the value of the pipeline.
Source: ClinicalTrials.gov (api_ct)